Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Behçet's syndrome: an update.

Hasan Yazici1

  • 1Division of Rheumatology, Department of Medicine, Cerrrahpa Medical Faculty, University of Istanbul, Aksarary 34303, Istanbul, Turkey. hyazici@attglobal.net

Current Rheumatology Reports
|May 15, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potential Confounding by Weight Loss: Comment on the article by Jorge et al.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

A critical look at disease classification/diagnosis criteria in rheumatology.

Current opinion in immunology·2026
Same author

EULAR recommendations for the management of Behçet's syndrome: 2025 update.

Annals of the rheumatic diseases·2026
Same author

A critical look at the evolution of randomized controlled trials: new and old ethical issues.

Current opinion in immunology·2026
Same author

Can we cure Behçet syndrome?

Current opinion in immunology·2025
Same author

Safety outcome trials in four mainline medical journals 30 years apart: a narrative review and the need for the transparency of informed consents.

Trials·2025
Same journal

Type I Interferonopathies: Fifteen Years On, From Concept to Therapeutic Perspectives.

Current rheumatology reports·2026
Same journal

Intensive Care Management of ANCA-associated Vasculitides: a Narrative Review.

Current rheumatology reports·2026
Same journal

The Role of Musculoskeletal Ultrasound in Psoriatic Arthritis: From Preclinical Detection to Treatment Monitoring.

Current rheumatology reports·2026
Same journal

Correction to: Is Gout and Autoinflammatory Disease?

Current rheumatology reports·2026
Same journal

Risks and Management of Glucocorticoid Therapy for Patients with Rheumatic Disease Having Surgery.

Current rheumatology reports·2026
Same journal

Perioperative Management Considerations for Patients with Systemic Lupus Erythematosus.

Current rheumatology reports·2026
See all related articles

Behçet's syndrome pathogenesis remains unclear, with potential endothelial dysfunction and human leukocyte antigen B51 involvement. While prognosis is guarded for young males, management is improving with new therapies.

Area of Science:

  • Rheumatology
  • Immunology
  • Vascular Medicine

Background:

  • Pathogenic mechanisms of Behçet's syndrome are not well understood.
  • The role of human leukocyte antigen B51 as an autoantigen is proposed.
  • The etiology of thrombophilia in Behçet's syndrome requires further elucidation.

Purpose of the Study:

  • To review the current understanding of Behçet's syndrome pathogenesis.
  • To discuss the potential role of endothelial pathology in disease development.
  • To evaluate the prognosis and management strategies for Behçet's syndrome.

Main Methods:

  • Literature review of existing studies on Behçet's syndrome.
  • Analysis of proposed autoantigens and etiological factors.
  • Assessment of prognostic indicators and treatment outcomes.

Related Experiment Videos

Main Results:

  • The exact pathogenic mechanisms remain largely unknown.
  • Endothelial pathology is suggested as a key factor in thrombophilia.
  • The association with familial Mediterranean fever may not be well-founded.
  • Prognosis is poorer for younger males, but the disease often remits.

Conclusions:

  • Further research is needed to fully understand Behçet's syndrome pathogenesis.
  • Improved clinical management is available with established and novel therapies.
  • Tumor necrosis factor-alpha inhibitors represent a potent treatment option.